SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 07/10/17 --  VistaGen Therapeutics Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today the appointment of Mark

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/29/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN) , a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today reported its financial results for its

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/22/17 --  VistaGen Therapeutics Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today a peer-reviewed publication

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/01/17 --  VistaGen Therapeutics Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that its largest

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/27/17 --  VistaGen Therapeutics Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today the peer-reviewed

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 03/29/17 --  VistaGen Therapeutics Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that the European Patent

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 03/08/17 --  VistaGen Therapeutics Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system ( CNS ) disorders, announced today that  Shawn Singh, Chief

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 02/13/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN) , a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system ( CNS ) disorders, today reported financial results for the

Presentation with live webcast on Tuesday, January 10th at 3:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Jan. 5, 2017 /PRNewswire/ --  VistaGen Therapeutics Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation therapies for depression and other central

VistaGen to receive upfront payment of $1.25M SOUTH SAN FRANCISCO, Calif., Dec. 14, 2016 /PRNewswire/ --  VistaGen Therapeutics Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation therapies for depression and other central nervous system ( CNS )